Cilostazol protects endothelial cells against lipopolysaccharide-induced apoptosis through ERK1/2- and P38 MAPK-dependent pathways

Korean Journal of Internal Medicine

Volumn 24, Issue 2, 2009, Pages 113-122

  Lim, Jong Hoon ^a   Woo, Jae Suk ^a   Shin, Yung Woo ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Apoptosis; Cilostazol; Endothelial cells; Extracellular signal regulated MAP kinases 1 2; p38 mitogen activated protein kinase; Protection

Indexed keywords

CASPASE; CILOSTAZOL; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOCHROME C; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN BCL 2; BAX PROTEIN, HUMAN; CARRIER PROTEIN; CREB1 PROTEIN, HUMAN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PHOSPHODIESTERASE INHIBITOR; PROTEIN KINASE INHIBITOR; TETRAZOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOSOLIC FRACTION; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MEDIATOR; MITOCHONDRIAL PERMEABILITY; MITOSIS INHIBITION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; CELL LINE; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TIME;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL LINE; CELL SURVIVAL; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; LIPOPOLYSACCHARIDES; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TETRAZOLES; TIME FACTORS;

EID: 67650716517     PISSN: 12263303     EISSN: None     Source Type: Journal    
DOI: 10.3904/kjim.2009.24.2.113     Document Type: Article

References (38)

1. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneinmittelforschung 1985;35:1144-1149.
2. Kohda N, Tani T, Nakayama S, et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res 1999;96:261-268.
3. Tanaka K, Gotoh F, Fukuuchi Y, et al. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 1989;20:668-673. (Pubitemid 19139099)
4. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678-686.
5. Lefer AM, Lefer DJ. Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol 1993;33:71-90. (Pubitemid 23116001)
6. Ten VS, Pinsky DJ. Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction. Curr Opin Crit Care 2002;8:242-250.
7. Minor T, Isselhard W.Role of the hepatovasculature in free radical mediated reperfusion damage of the liver. Eur Surg Res 1993;25:287-293.
8. Scalia R, Pearlman S, Campbell B, Lefer AM. Time course of endothelial dysfunction and neutrophil adherence and infiltration during murine traumatic shock. Shock 1996;6:177-182. (Pubitemid 126727758)
9. Hack CE, Zeerleder S.The endothelium in sepsis: source of and a target for inflammation. Crit Care Med 2001;29(7 Suppl):S21-S27.
10. Kim KY, Shin HK, Choi JM, Hong KW. Inhibition of LPS-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 2002;300:709-715. (Pubitemid 34106268)
11. Hong KW, Kim KY, Shin HK, et al. Cilostazol prevents tumor necrosis factor-alpha-induced cell death by suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and activation of Akt/cyclic AMP response element-binding protein phosphorylation. J Pharmacol Exp Ther 2003;306:1182-1190.
12. Choi JM, Shin HK, Kim KY, Lee JH, Hong KW. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 2002;300:787-793.
13. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-1912.
14. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004;23:2838-2849. (Pubitemid 38638846)
15. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-252.
16. Pastorino JG, Chen ST, Tafani M, Snyder JW, Farber JL. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem 1998;273:7770-7775. (Pubitemid 28152810)
17. Lemasters JJ, Nieminen AL, Qian T, et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1998;1366:177-196. (Pubitemid 28467031)
18. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-18632. (Pubitemid 28334795)
19. Cirillo PF, Pargellis C, Regan J. The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr Top Med Chem 2002;2:1021-1035.
20. Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 2001;98:13681-13686.
21. Ozoren N, Kim K, Burns TF, Dicker DT, Moscioni AD, El-Deiry WS. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000;60:6259-6265. (Pubitemid 30952119)
22. Akita K, Ohtsuki T, Nukada Y, et al. Involvement of caspase-1 and caspase-3 in the production and processing of mature human interleukin 18 in monocytic THP1 cells. J Biol Chem 1997;272:26595-26603. (Pubitemid 27458882)
23. van Noorden CJ. The history of Z-VAD-FMK, a tool for understanding the significance of caspase inhibition. Acta Histochem 2001;103:241-251.
24. Talanian RV, Quinlan C, Trautz S, et al. Substrate specificities of caspase family proteases. J Biol Chem 1997;272:9677-9682. (Pubitemid 27171628)
25. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 1998;60:619-642. (Pubitemid 28157889)
26. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001;2:599-609. (Pubitemid 33674011)
27. Nishihara H, Hwang M, Kizaka-Kondoh S, Eckmann L, Insel PA. Cyclic AMP promotes cAMP-responsive element-binding protein-dependent induction of cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through ERK1/2 and p38 MAPK. J Biol Chem 2004;279:26176-26183. (Pubitemid 38798763)
28. Sprick MR, Walczak H. The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta 12004;644:125-132.
29. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999;27:1230-1251. (Pubitemid 29379358)
30. Bannerman DD, Tupper JC, Ricketts WA, Bennett CF, Winn RK, Harlan JM. A constitutive cytoprotective pathway protects endothelial cells from lipopolysaccharide-induced apoptosis. J Biol Chem 2001;276:14924-14932. (Pubitemid 37373373)
31. Munshi N, Fernandis AZ, Cherla RP, Park IW, Ganju RK. Lipopolysaccharide-induced apoptosis of endothelial cells and its inhibition by vascular endothelial growth factor. J Immunol 2002;168:5860-5866. (Pubitemid 34556174)
32. Hoyt DG, Mannix RJ, Gerritsen ME, Watkins SC, Lazo JS, Pitt BR. Integrins inhibit LPS-induced DNA strand breakage in cultured lung endothelial cells. Am J Physiol 1996;270:L689-L694.
33. Wort SJ, Evans TW. The role of the endothelium in modulating vascular control in sepsis and related conditions. Br Med Bull 1999;55:30-48.
34. Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S, et al. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation.J Exp Med 1997;186:1831-1841.
35. Zhang XM, Morikawa A, Takahashi K, et al. Localization of apoptosis (programmed cell death) in mice by administration of lipopolysaccharide. Microbiol Immunol 1994;38:669-671. (Pubitemid 24264895)
36. Cobb MH. MAP kinase pathways. Prog Biophys Mol Biol 1999;71:479-500.
37. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-P38 MAP kinases on apoptosis. Science 1995;270:1326-11231
38. Xiang H, Wang J, Boxer LM. Role of the cyclic AMP response element in the Bcl-2 Promoter in the regulation of endogenous Bcl-2 expression and apoptosis in murine B Cells. Mol Cell Biol 2006;26:8599-8606. (Pubitemid 44748591)